Scientists warn diabetes patients may have increased bleeding from taking aspirin
LONDON Scientists from the University of Dundee have released a report that states taking aspirin may lead to increased internal bleeding and other complications in diabetes patients.
Many people take aspirin daily to help reduce the risk of heart attack. But, scientists have concluded that taking aspirin doesn’t mitigate the risk of heart attack for diabetes patients, unless they already had heart disease.
Following an eight-year study that followed 1,276 diabetes patients who took aspirin, a placebo or an antioxidant to help prevent heart disease, researchers concluded that aspirin should be taken only by patients already dealing with heart disease or who have suffered a stroke.
Advertising council makes recommendations on Constellation Wines’ dietary claims
NEW YORK The National Advertising Division of the Council of Better Business Bureaus on Tuesday determined that Constellation Wines U.S./PolyPhenolics provided reasonable support for certain performance claims made for the company’s dietary supplement MegaNatural-BP, but recommended the company discontinue certain claims to avoid consumer confusion.
NAD was concerned that that the claim “Provide relief with half the cost, half the dose,” did not clearly identify the object of the comparison and suggested that consumers with high blood pressure could replace prescribed medication with a supplement.
NAD recommended that the advertiser discontinue the claim, “Provide relief with half the cost, half the dose and half the time” but noted that the advertiser can continue to discuss the differences between MegaNatural-BP and the competing Antigen Converting Enzyme (ACE) inhibitors which take 4-6 weeks of regular supplementation to work.
NAD recommended that to avoid the potential for any consumer confusion, and consistent with the findings of the studies on which it relies, the advertiser clearly and conspicuously disclose that MegaNatural-BP could be used as a part of a lifestyle management program for people with prehypertension and metabolic syndrome, and clearly state that consumers should “Consult your doctor before taking MegaNatural-BP.”
The company, in its advertiser’s statement, said it “understands NAD’s decision as written and appreciates your thorough and well-explained rationale. Polyphenolics agrees to modify its advertising as recommended.”
Alcon reports third-quarter eye care sales increase
HUNENBERG, Switzerland Alcon Thursday morning reported an increase in consumer eye care sales of 10.5 percent to $223.7 million for its third quarter ended Sept. 30. Sales of contact lens disinfectants grew 2.6 percent, as Opti-Free RepleniSH and Opti-Free Express multipurpose disinfecting solutions continued to maintain their combined market share in the United States.
Alcon currently fields a 38.7 percent market share of the U.S. contact lens care license market, the company reported, remaining the only branded marketer to own a greater market share than private label alternatives and exceeding market share of competitors Bausch & Lomb and AMO, which together possess less than 25 percent market share. “We gained significant market share on a global basis as a result of the product recalls by competitors in 2006 and 2007,” commented Cary Rayment, Alcon chairman, president and chief executive officer during a conference call with analysts. “We have been able to maintain the share we gained in the past two years,” he said.
“We are the only brand that exceeds private label in the U.S.,” he added. “We believe this is a result of our success in communicating the efficacy and safety of the Opti-Free RepleniSH brand to the professional channel where we get about seven out of 10 recommendations from optometrists in the U.S.”
Sales of artificial tears products increased 28 percent, led by increases in the global sales of Systane lubricant eye drops and the U.S. launch of Systane Ultra in July. “Quarterly sales have almost tripled in the last five years, reflecting increased market demand and market share gains in this segment,” Rayment said.
Alcon reported global sales of $1.5 billion for the third quarter, an increase of 14.1 percent.